S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
NASDAQ:PPD

PPD (PPD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$47.28
$47.28
50-Day Range
$47.10
$47.41
52-Week Range
$31.54
$47.41
Volume
N/A
Average Volume
1.91 million shs
Market Capitalization
$16.61 billion
P/E Ratio
47.28
Dividend Yield
N/A
Price Target
N/A
PPD stock logo

About PPD Stock (NASDAQ:PPD)

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

PPD Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Parma man missing since April 7: Police
See More Headlines
Receive PPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial Physical Research
Sub-Industry
N/A
Current Symbol
NASDAQ:PPD
Fax
N/A
Employees
26,000
Year Founded
N/A

Profitability

Net Income
$153.69 million
Pretax Margin
7.31%

Debt

Sales & Book Value

Annual Sales
$4.68 billion
Cash Flow
$1.99 per share
Book Value
($1.21) per share

Miscellaneous

Free Float
344,718,000
Market Cap
$16.61 billion
Optionable
Not Optionable
Beta
1.96
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Should I Buy PPD Stock? PPD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in PPD, Inc.:

  • PPD, Inc. has a strong presence in the biopharmaceutical industry worldwide, offering a wide range of drug development services.
  • David Johnston, Ph.D., the executive vice president and global head of clinical development services at PPD, brings extensive experience and expertise to the company.
  • PPD's Accelerated Enrollment Solutions (AES) business provides data-driven patient recruitment for clinical trials, enhancing efficiency and speed in trial execution.
  • Recent collaborations and partnerships, such as the one with Science 37 for digital trials, demonstrate PPD's commitment to innovation and staying at the forefront of industry trends.
  • Considering the current stock price and market trends, PPD, Inc. shows potential for growth and value appreciation.

Cons

Investors should be bearish about investing in PPD, Inc. for these reasons:

  • Market volatility and regulatory challenges in the biopharmaceutical industry can impact PPD's operations and financial performance.
  • Dependency on external factors such as government regulations, clinical trial outcomes, and industry competition may pose risks to investment returns.
  • Fluctuations in global economic conditions and healthcare spending could affect the demand for PPD's services and solutions.
  • Uncertainties related to the success of new drug developments and clinical trials could influence the company's revenue streams and profitability.
  • Investors need to carefully assess the competitive landscape and potential threats to PPD's market position to make informed investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these PPD pros and cons to contact@marketbeat.com.

PPD Stock Analysis - Frequently Asked Questions

How were PPD's earnings last quarter?

PPD, Inc. (NASDAQ:PPD) announced its quarterly earnings data on Wednesday, October, 27th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.05. The firm earned $1.56 billion during the quarter, compared to the consensus estimate of $1.41 billion. PPD had a net margin of 6.11% and a negative trailing twelve-month return on equity of 89.48%. The firm's revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.15 earnings per share.

What other stocks do shareholders of PPD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PPD investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), Salesforce (CRM), Pfizer (PFE), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), RTX (RTX) and Verizon Communications (VZ).

When did PPD IPO?

PPD (PPD) raised $1.5 billion in an IPO on Thursday, February 6th 2020. The company issued 60,000,000 shares at a price of $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair served as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers.

This page (NASDAQ:PPD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners